MediciNova, Inc. Form 10-Q Summary
Business context and reporting period
MediciNova is a development-stage biopharmaceutical company focused on therapeutics for serious diseases with unmet medical needs. Its primary programs are MN-166 (ibudilast) for neurological and other disorders and MN-001 (tipelukast) for fibrotic and other diseases. The pipeline also includes MN-221 and MN-029. This unaudited report covers the three and six months ended June 30, 2023, filed August 9, 2023.
Financial condition and key metrics
| Metric | Three months ended June 30, 2023 | Six months ended June 30, 2023 |
|---|---|---|
| Revenue | None reported | None reported |
| Research, development and patents expense | $1.7 million | $3.2 million |
| General and administrative expense | $1.6 million | $3.1 million |
| Total operating expenses | $3.3 million | $6.3 million |
| Operating loss | $3.3 million | $6.3 million |
| Interest income | $0.5 million | $1.0 million |
| Net loss | $2.9 million | $5.8 million |
| Basic and diluted loss per share | $0.06 | $0.12 |
| Net cash used in operating activities | Not separately reported | $5.6 million |
At June 30, 2023, cash and cash equivalents were $52.9 million, compared with $18.5 million at December 31, 2022. Current investments declined from $40.0 million to zero as certificates of deposit were disposed of. Working capital was $50.7 million. Total assets were $68.7 million and stockholders’ equity was $65.2 million.
Total liabilities were $3.5 million, including $0.7 million of operating lease liabilities. The filing does not report outstanding debt or borrowings. The company had 49,046,246 common shares outstanding and 8,286,416 anti-dilutive stock options outstanding at June 30, 2023.
Material changes versus prior comparable periods
- Second-quarter research, development and patents expense decreased $0.9 million, to $1.7 million from $2.6 million, primarily because of lower MN-221 and MN-166 manufacturing expenses, partly offset by higher MN-001 expenses.
- Six-month research, development and patents expense decreased $1.5 million, to $3.2 million from $4.7 million.
- General and administrative expense increased $0.1 million in the quarter and $0.3 million for the six-month period, primarily due to higher performance-based stock option expense.
- Net loss improved to $2.9 million for the quarter from $4.0 million and to $5.8 million for six months from $7.4 million.
- Interest income increased substantially, to $0.5 million for the quarter and $1.0 million for six months, due primarily to higher interest rates on cash and certificates of deposit.
- Six-month investing cash flow was $39.9 million, reflecting proceeds from the disposal of certificates of deposit. This, rather than operating performance, was the principal reason cash increased by $34.4 million during the period.
- Other expense for the six months was $0.5 million, primarily reflecting penalties on early disposal of certificates of deposit.
Guidance, outlook, risks and unusual items
- Management expects research and development spending to increase through the remainder of 2023 as development programs progress.
- Management believes available working capital is sufficient to fund operations at least through the end of 2024, but states that it cannot assure sufficient resources to conduct all planned research and development programs.
- The company expects substantial net losses for the next several years and has an accumulated deficit of $412.9 million as of June 30, 2023.
- The company may seek strategic alliances and non-dilutive funding, including grants, to support development of MN-166 and MN-001. It also maintains an ATM facility permitting up to $75.0 million of aggregate common-stock sales; no shares were sold under the facility during the reported periods.
- Potential future milestone payments were $10.0 million for MN-166 and MN-001 and $16.5 million for other products. Timing is uncertain and depends on development progress. No milestone payments were made during the reported periods.
- Key risks include clinical-trial delays or failures, inability to obtain regulatory approvals, dependence on MN-166 and MN-001, inability to raise additional capital, reliance on third-party manufacturers and trial providers, intellectual-property disputes, product-liability exposure, competition, and possible effects from COVID-19 or other health emergencies.
- The filing reports no material legal proceedings, no defaults, no unregistered securities sales, and no material changes to previously disclosed risk factors.
- The company adopted a new 2023 Equity Incentive Plan in June 2023. As of June 30, 2023, 1,648,151 shares remained available for future grants.
Important facts for investors to verify
- Verify the sustainability of the $52.9 million cash balance, including the extent to which it reflects one-time liquidation of certificates of deposit rather than recurring cash generation.
- Assess projected cash burn and whether management’s statement that liquidity extends through the end of 2024 supports the planned clinical and development programs.
- Track clinical, regulatory and enrollment milestones for MN-166 and MN-001, including the RECLAIM Long COVID trial and other investigator- or grant-funded programs.
- Evaluate potential dilution from the $75.0 million ATM facility, outstanding options, and the 2023 Equity Incentive Plan.
- Review the timing and probability of the disclosed contingent milestone payments and any future royalty obligations.
- Confirm that no revenue-generating product has yet been commercialized; the filing does not provide a clear recurring revenue value.